Search Results - Shanu Modi

Refine Results
  1. 1
    Ganetespib: research and clinical development

    Ganetespib: research and clinical development by Shanu Modi, Komal Jhaveri

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    HER2 breast cancer therapies: a review

    HER2 breast cancer therapies: a review by Shanu Modi, Conleth G. Murphy

    Published 2009
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Unlocking the potential of antibody–drug conjugates for cancer therapy

    Unlocking the potential of antibody–drug conjugates for cancer therapy by Joshua Z. Drago, Shanu Modi, Sarat Chandarlapaty

    Published 2021
    Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions

    Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions by Emanuela Ferraro, Joshua Z. Drago, Shanu Modi

    Published 2021
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers

    Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers by Komal Jhaveri, Tony Taldone, Shanu Modi, Gabriela Chiosis

    Published 2011
    Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment

    Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment by Hardik Patel, Shanu Modi, Gabriela Chiosis, Tony Taldone

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Beyond HER2: Targeting the ErbB receptor family in breast cancer

    Beyond HER2: Targeting the ErbB receptor family in breast cancer by Joshua Z. Drago, Emanuela Ferraro, Nour Abuhadra, Shanu Modi

    Published 2022
    Get full text
    Revisão
    Save to List
    Saved in:
  8. 8
    Incidence of chemotherapy‐induced, long‐term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane

    Incidence of chemotherapy‐induced, long‐term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane by Monica Fornier, Shanu Modi, Katherine S. Panageas, Larry Norton, Clifford A. Hudis

    Published 2005
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer

    Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer by Giuseppe Curigliano, Rebecca Dent, H. Earle, Shanu Modi, Paolo Tarantino, Giulia Viale, Sara M. Tolaney

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Chaperome heterogeneity and its implications for cancer study and treatment

    Chaperome heterogeneity and its implications for cancer study and treatment by Tai Wang, Anna Rodina, Mark Dunphy, Adriana Corben, Shanu Modi, Mónica L. Guzmán, D.T. Gewirth, Gabriela Chiosis

    Published 2018
    Get full text
    Revisão
    Save to List
    Saved in:
  11. 11
    A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer

    A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer by Muralidhar Beeram, Ian E. Krop, Howard A. Burris, Sandhya Girish, Wei Yu, Michael W. Lu, Scott N. Holden, Shanu Modi

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

    Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer by Ian E. Krop, Shanu Modi, Patricia LoRusso, Mark D. Pegram, Ellie Guardino, Betsy Althaus, Dan Lu, Alexander Strasak, Anthony Elias

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer

    Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer by Azael Freites‐Martínez, Jerry Shapiro, Donald Chan, Monica Fornier, Shanu Modi, Devika Gajria, Stephen W. Dusza, Shari Goldfarb, Mario E. Lacouture

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

    Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies by Paolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti, Shanu Modi, Aditya Bardia, Sara M. Tolaney, Javier Cortés, Jean‐Charles Soria, Giuseppe Curigliano

    Published 2021
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  15. 15
    The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation

    The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation by T. Jonathan Yang, Monica Morrow, Shanu Modi, Zhigang Zhang, Kate Krause, Chun Siu, Beryl McCormick, Simon N. Powell, Alice Y. Ho

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    A Reversible Case of Advanced Interstitial Lung Disease in a Patient with HER2 Low Metastatic Breast Cancer Treated with Trastuzumab Deruxtecan

    A Reversible Case of Advanced Interstitial Lung Disease in a Patient with HER2 Low Metastatic Breast Cancer Treated with Trastuzumab Deruxtecan by Felipe Marques da Costa, Milena Tenório Cerezoli, Augusto Kreling Medeiros, Gabriela Machado Novaes, B.R. da Silva, Fernando Cotait Maluf, Shanu Modi

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors

    A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors by Komal Jhaveri, Kathy D. Miller, Lee S. Rosen, Bryan P. Schneider, Linnea Chap, Alison L. Hannah, Ziyang Zhong, Weining Ma, Clifford A. Hudis, Shanu Modi

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer

    A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer by Shanu Modi, Cristina Saura, Charles Henderson, Nancy U. Lin, Reshma Mahtani, Jill Goddard, Eduard Ródenas‐Alesina, Clifford A. Hudis, Joyce O’Shaughnessy, José Baselga

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies

    Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies by Shunji Takahashi, Hideaki Bando, Ichiro Kinoshita, Shanu Modi, Junji Tsurutani, Yung‐Jue Bang, Yuta Sato, Shunsuke Nakatani, Caleb Lee, Masahiro Sugihara, Yasuyuki Okuda, Hiroji Iwata

    Published 2024
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer

    Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer by Sarat Chandarlapaty, Rita A. Sakr, Dilip D. Giri, Sujata Patil, Adriana Heguy, Monica Morrow, Shanu Modi, Larry Norton, Neal Rosen, Clifford A. Hudis, Tari A. King

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: